Actively Recruiting
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Led by Hunan Province Tumor Hospital · Updated on 2024-06-04
15000
Participants Needed
1
Research Sites
334 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
CONDITIONS
Official Title
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Lung cancer confirmed by histopathology
- Treated with chemotherapy with or without checkpoint inhibitors
- ECOG performance status of 0 or 1
- Predicted survival of at least 12 weeks
- Adequate bone marrow and organ function
- Presence of measurable lesions according to RECIST 1.1
- Stable brain metastases allowed
You will not qualify if you...
- Patients who do not meet the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
CONTACT
N
Nong Yang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
12
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here